(ALKS) Alkermes plc BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(ALKS) Alkermes plc Complete Analysis Pack
Visual. Strategic. Downloadable.
This Alkermes plc BCG Matrix helps you see how the company’s products or business units are positioned across Stars, Cash Cows, Question Marks, and Dogs for strategy and portfolio analysis. The content on this page is a real preview of the actual report, so you can review the format and sample insights before buying. Purchase the full version to get the complete ready-to-use analysis.
Stars
LYBALVI schizophrenia 2021
LYBALVI was approved in 2021 for schizophrenia in adults, and it combines olanzapine with samidorphan in one oral dose. In Alkermes plc’s BCG view, it is still a Star in an early growth phase, not yet a mature cash engine like older CNS brands. Its role is to expand share in a large, long-treated schizophrenia market while the portfolio shifts beyond legacy products.
LYBALVI bipolar I disorder 2021
Approved in 2021 for bipolar I disorder in adults, LYBALVI added a second commercial indication to Alkermes plc's oral franchise. That wider label gives the product a larger growth runway than a single-indication launch, and Alkermes plc still markets it alongside schizophrenia. In BCG terms, the mix of expansion potential and repeat prescribing supports a Stars profile.
VUMERITY relapsing MS 2019
VUMERITY, approved in 2019, is Alkermes plc’s oral diroximel fumarate for relapsing forms of multiple sclerosis. The Stars case fits a large, still-active market: about 1 million people in the U.S. live with MS, and roughly 85% are diagnosed first with relapsing disease. Oral dosing helps keep it relevant against injectables and infusions.
ARISTADA schizophrenia 2015
ARISTADA, approved in 2015 for adult schizophrenia, fits Alkermes plc’s Stars bucket because it is a long-acting injectable aripiprazole franchise with durable repeat dosing. Its monthly and extended-interval use helps keep patients in LAI care pathways, where persistence is often stronger than with daily oral therapy. In Alkermes plc’s 2025-2026 mix, ARISTADA remains a key branded asset tied to ongoing refill-based revenue.
- 2015 approval for adult schizophrenia
- Long-acting injectable aripiprazole
- Repeat dosing supports retention
- LAI pathway adoption drives stickiness
ARISTADA INITIO start regimen 2021
ARISTADA INITIO is the starter regimen for ARISTADA, helping patients begin long-acting aripiprazole treatment in one day and supporting faster franchise uptake. In Alkermes plc's injectable antipsychotic platform, it fits the "Star" profile because it drives access and switch rates into a growing LAI market, which reached roughly $7 billion globally in 2025. Its value is tied to ARISTADA's broader prescription base and recurring treatment flow.
- One-day start supports faster initiation
- Tied to ARISTADA franchise growth
- Backs Alkermes plc LAI expansion
Alkermes’ Star Products: LYBALVI, ARISTADA, and VUMERITY Drive Growth
Alkermes plc’s Stars are the products with the clearest growth and repeat-use pull: LYBALVI, ARISTADA, ARISTADA INITIO, and VUMERITY. LYBALVI had 2025 net sales of about $420 million, while ARISTADA generated about $541 million and VUMERITY about $294 million, showing the scale behind the franchise. ARISTADA INITIO supports faster LAI starts and helps convert new patients into recurring use.
| Product | 2025 value | Star driver |
|---|---|---|
| LYBALVI | $420M | Two-indication growth |
| ARISTADA | $541M | Repeat LAI dosing |
| VUMERITY | $294M | Oral MS demand |
What is included in the product
Detailed Word Document
Alkermes plc BCG Matrix maps its portfolio to spot Stars, Cash Cows, Question Marks, and Dogs for invest/hold/divest.
Editable Excel File
One-page Alkermes plc BCG Matrix that quickly spots pain points and priority moves.
Reference Sources
Provides a clear source trail for Alkermes plc, strengthening credibility and helping decision-makers verify key assumptions fast.
Cash Cows
VIVITROL alcohol dependence 2006
VIVITROL, approved in 2006 for alcohol dependence, is one of Alkermes plc’s longest-running marketed brands. Its once-monthly 380 mg injection and long prescribing history support steady repeat use. In FY2025, this mature franchise helped Alkermes plc generate recurring cash flow from an established patient base.
VIVITROL opioid dependence relapse prevention 2006
VIVITROL, approved in 2006 for relapse prevention after opioid detoxification, gives Alkermes plc a second use for the same monthly injectable brand. That dual-label setup helps keep demand steady and low growth, which fits a Cash Cow in the BCG Matrix. In 2025, it still supported recurring branded revenue and cash flow from one product family.
RISPERDAL CONSTA Janssen royalty
RISPERDAL CONSTA is a long-established long-acting risperidone franchise, so Alkermes plc earns collaboration economics from a mature, low-growth market. That makes it a classic Cash Cow: steady royalties, modest reinvestment needs, and limited upside tied to new patient growth. The asset still helps fund Alkermes plc’s higher-growth pipeline and commercial spend.
INVEGA SUSTENNA paliperidone LAI
INVEGA SUSTENNA is a mature monthly paliperidone LAI and a clear Cash Cow for Alkermes plc through Janssen collaboration economics. Janssen reported global INVEGA SUSTENNA sales of about $4.1 billion in 2025, while growth stayed modest versus newer schizophrenia launches, so the brand remains large but slow-moving.
- Large, steady schizophrenia franchise
- Monthly LAI supports repeat use
- Alkermes earns collaboration economics
- Growth is slower than new products
XEPLION INVEGA TRINZA TREVICTA
XEPLION, INVEGA TRINZA, and TREVICTA are extended-interval paliperidone palmitate LAIs with mature schizophrenia demand, so they fit Cash Cows: high share in a steady market, low growth, and reliable cash generation. TREVICTA is the 3-month version, while INVEGA TRINZA and XEPLION anchor long-acting maintenance use. For Alkermes plc analysis, their value is the cash they can throw off, not expansion.
- Established LAI schizophrenia brands
- Stable, mature demand profile
- Cash generation over growth
- Low incremental investment need
Alkermes’ Mature Brands Keep Cash Flowing in FY2025
In FY2025, Alkermes plc's Cash Cows were its mature LAI and branded franchises, led by VIVITROL and collaboration assets tied to RISPERDAL CONSTA, INVEGA SUSTENNA, INVEGA TRINZA, XEPLION, and TREVICTA. These products sit in slow-growth markets, but they still generate recurring cash with limited reinvestment needs.
| Asset | FY2025 signal |
|---|---|
| VIVITROL | Monthly, mature cash flow |
| INVEGA SUSTENNA | Janssen sales about $4.1B |
Preview Before You Purchase
Alkermes plc Reference Sources
The Alkermes plc BCG Matrix preview you see here is the exact same document you’ll receive after purchase. No watermarks, no demo pages—just the full, ready-to-use report. It’s formatted for clear strategic analysis and professional presentation. Once purchased, the file is available for immediate download.
Dogs
ALKS 5461 0 approvals
ALKS 5461 was an adjunct treatment candidate for major depressive disorder, but it received no approval and Alkermes plc later discontinued the program after regulatory setbacks. The asset generated no commercial product sales, so it fits the Dogs quadrant in the Alkermes plc BCG Matrix. That means it consumed R&D capital without creating revenue.
Legacy terminated CNS programs 0 sales
Legacy terminated CNS programs generated 0 sales in fiscal 2025 and sit in Alkermes plc’s dog bucket. These older neuroscience candidates never reached approval, so they still reflect historic R and D spend but no current cash flow. With low share and no market access, they add cost, not growth.
Discontinued preclinical assets 0 market share
Alkermes plc's discontinued preclinical assets stayed at 0 market share and never crossed the commercialization threshold. They produced no branded product line and no sales base, so they added no direct revenue in 2025. As of end-2025, their strategic value was minimal versus Alkermes plc's $1.4 billion FY2025 revenue base.
Non-core historical pipeline 0 growth
Alkermes plc’s non-core historical pipeline is a clear Dog: older internal programs have been de-prioritized, carry no visible market share, and show 0% growth. In FY2025, Alkermes generated $1.5 billion in total revenue, so these legacy assets were immaterial versus core products. Capital is better kept out of these programs.
- Older programs, no priority
- No visible market share
- Growth outlook: 0%
- Do not fund further
Historical write-off programs 0 cash generation
Alkermes plc's historical write-off programs are legacy assets that were exited or fully impaired, so they generate 0 cash for current operations. That matches the BCG "dog" profile: low share, no growth, and no reinvestment payoff. They drain attention, but not because they still create value.
- Legacy programs: written down or exited
- Current cash generation: 0
- BCG fit: low-growth, low-share dog
- Value today: none to operating cash flow
Alkermes’ Legacy CNS Dogs: Zero Sales, Zero Share, Zero Payoff
Alkermes plc’s Dogs are the discontinued legacy CNS programs: they generated 0 sales in FY2025, held no market share, and added no current cash flow. They fit the low-share, no-growth BCG dog bucket, so further funding has no clear payoff versus Alkermes plc’s $1.5 billion FY2025 revenue base.
| Metric | FY2025 |
|---|---|
| Dog assets sales | 0 |
| Market share | 0% |
| Alkermes plc revenue | $1.5 billion |
Question Marks
Nemvaleukin alfa mucosal melanoma
Nemvaleukin alfa, an engineered IL-2 pathway fusion protein, was advanced in oncology development as a Question Mark in Alkermes plc’s BCG matrix. Mucosal melanoma is rare, about 1% of melanomas, and has high unmet need, but clinical and regulatory outcomes remain uncertain despite early response signals in small studies.
Nemvaleukin alfa platinum-resistant ovarian cancer
Nemvaleukin alfa in platinum-resistant ovarian cancer is another late-stage oncology bet for Alkermes plc, but this market is hard to crack. About 70% of ovarian cancers are found at advanced stage, and platinum resistance affects roughly 20%-30% of patients after first-line treatment. The asset needs strong Phase 2/3 data to turn this question mark into real commercial value.
ALKS 2680 narcolepsy type 1
ALKS 2680 is a Question Mark in Alkermes plc's BCG Matrix: an oral orexin 2 receptor agonist in development for narcolepsy type 1, a rare sleep disorder with an estimated prevalence of about 25 to 50 per 100,000 people. The market is growing, the unmet need is clear, and the asset still has no sales. If clinical data land well, it could move toward a future Star.
ALKS 2680 narcolepsy type 2
ALKS 2680 also targets narcolepsy type 2, so Alkermes plc could address a larger patient pool than narcolepsy type 1 alone. U.S. narcolepsy affects about 1 in 2,000 people, and type 2 is often the larger share of cases, but ALKS 2680 still has 0% market share because it is not approved.
- Broader market than one diagnosis
- Type 2 expands patient reach
- Current share remains zero
ALKS 2680 idiopathic hypersomnia
ALKS 2680 targets idiopathic hypersomnia, a sleep disorder that affects an estimated 37 to 50 people per 100,000 adults, so the unmet need is real. But Alkermes plc has no commercial sales here yet, making it a classic high-potential, low-share question mark.
The asset is still pre-launch and the market is unproven, so near-term value depends on clinical data, dosing, and payer uptake. For Alkermes plc, that means upside can be large, but cash generation is still zero.
High unmet need, limited treatment options
Pre-commercial, no revenue yet
Potential orexin-based growth optionality
Alkermes’ High-Upside Bets: Big Potential, No Sales Yet
Alkermes plc’s Question Marks are still early, high-upside bets with no sales yet. Nemvaleukin alfa and ALKS 2680 both target large unmet-need niches, but value now depends on late-stage data, approval risk, and payer adoption. ALKS 2680 also keeps broader upside through narcolepsy type 2 and idiopathic hypersomnia.
| Asset | Status | Key point |
|---|---|---|
| Nemvaleukin alfa | Clinical | No revenue; oncology risk high |
| ALKS 2680 | Pre-launch | 0% share; broader sleep upside |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.